SELECTIVE ANDROGEN RECEPTOR MODULATOR
Ligandrol (LGD 4033) is an investigational selective androgen receptor modulator for treatments of conditions such as muscle wasting and osteoporosis, discovered by Ligand Pharmaceuticals and currently under development by Viking Therapeutics.
Use left/right arrows to navigate the slideshow or swipe left/right if using a mobile device